Search
Afelimomab
go.drugbank.com/drugs/DB04956ExperimentalAfelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.
PM02734
go.drugbank.com/drugs/DB05158InvestigationalPM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.
PF-06291874
go.drugbank.com/drugs/DB15065InvestigationalPF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes
2'-Fucosyllactose
go.drugbank.com/drugs/DB16052Investigational2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-tnf Therapy).
Leuvectin
go.drugbank.com/drugs/DB17303InvestigationalLeuvectin (formerly known as VCL-1102) is a component of gene therapy along with cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE
Deutarserine
go.drugbank.com/drugs/DB19057InvestigationalDeutarserine is under investigation in clinical trial NCT04158687 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia).
Efzofitimod
go.drugbank.com/drugs/DB16453InvestigationalEfzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. It is a selective modulator of neuropilin-2 that downregulates the innate and ad...
Ronacaleret
go.drugbank.com/drugs/DB05255InvestigationalRonacaleret is a calcium-sensing receptor antagonist.
Telcagepant
go.drugbank.com/drugs/DB12228InvestigationalTelcagepant has been investigated for the treatment of Migraine.
Cirazoline
go.drugbank.com/drugs/DB09202ExperimentalCirazoline has also been shown to decrease food intake in rats, purportedly through activation of α1-adrenoceptors in the paraventricular nucleus in the hypothalamus of the brain.